Navigation Links
Researchers identify proteins in lung cancer cells that may provide potential drug targets
Date:11/24/2009

(Boston) Researchers from Boston University School of Medicine (BUSM) and the Boston University Biomedical Engineering Department have identified a number of proteins whose activation allows them to distinguish between cancer and normal cells with almost 97 percent accuracy. In addition, the BU researchers have developed a new computational strategy to analyze this data and specifically identify key biological pathways (molecular circuits) that are active in cancer and "dormant" in normal cells. The study which appears in the November 25th issue of PLoS ONE, will ultimately lead to the development of drugs specifically aimed to inhibit these proteins.

According to the BU researchers, there are many features that make cancer cells different from normal cells. They look different histologically, they proliferate and divide at different rates, they are immortal unlike normal cells, and are less communicative with their neighbor cells. They are also more "selfish" in refusing to commit suicide (programmed cell death) which normal cells do when their genomes become unstable.

Much of the cellular machinery involved with these biological processes is controlled by a command control and communication system called signal transduction. Signal transduction is in large part controlled by a process called phosphorylation. When a protein is phosphorylated it either becomes active or repressed depending on its special function. "Therefore, identifying the phosphorylation status of proteins in cancer cells versus normal cells provides us with a unique ability to understand and perhaps intervene with the command and control center of cancer cells," said co-senior author Simon Kasif, PhD, who is the co-director of the Center of Advanced Genomic Technology and a professor in the department of biomedical engineering at BU. "Drugs are most effective on cancers when they attack the proteins that are activated," he added.

While cancers are highly heterogeous in their make-up, the BU researchers believe that a drug that would target this collection of proteins would be effective treatment for most lung cancers.

"This is the first statistically validated phosphopeptide signature to diagnose any disease, much less cancer or lung cancer," explained senior co-author Martin Steffen, MD, PhD, an assistant professor of pathology and laboratory medicine at BUSM, and director, Proteomics Core Facility at BUSM.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research
2. Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps
3. Researchers identify role of gene in tumor development, growth and progression
4. On the trail of a vaccine for Lyme disease: Yale researchers target tick saliva
5. UCLA researchers create fly paper to capture circulating cancer cells
6. Researchers focus on helping dying patients take care of unfinished business
7. Mount Sinai researchers to test first gene therapy For Alzheimers patients
8. Wistar researchers show targeting normal cells in tumors slows growth
9. K-State researchers studying link between climate change and cattle nutritional stress
10. Cornell Researchers Identify a Weak Link in Cancer Cell Armor
11. Researchers notch a victory toward new kind of cancer drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... Valley, CA (PRWEB) , ... June 27, 2017 , ... ... since 2001 suffer from PTSD. Yet less than 20% will receive adequate care due ... those with PTSD won't receive any care at all. And left untreated, veterans are ...
(Date:6/26/2017)... Torrance, CA (PRWEB) , ... June 26, 2017 , ... ... treatments. Smile aesthetics can be one of the most noticeable aspects of a person’s ... approachable. While not everyone is born with beautiful, balanced teeth, everyone can have the ...
(Date:6/26/2017)... ... 26, 2017 , ... Maryland’s soybean farmers have improved the ... by the United Soybean Board. , Thanks to the responsible use of ... productivity on less land per bushel, the report says. The United Soybean Board’s ...
(Date:6/26/2017)... ... June 26, 2017 , ... KICKICO , a protocol built on ... to solve many catastrophic issues within funding campaigns. KICKICO developers are testing the platform, ... crowdfunding - the raising of funds through the power of many - has been ...
(Date:6/25/2017)... ... ... Republicans in the United States Senate on Thursday released their version ... It differs significantly from the American Health Care Act, which the House passed in ... House will have to take up the Senate version as-is, if it passes. , ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)... LAWRENCE, Mass. , June 2, 2017  NxStage ... advancing renal care, today announced new findings demonstrating positive ... NxStage ® System One™. The data will be ... 2017, in Madrid, Spain . ... Knowledge to Improve Home Dialysis Network in ...
(Date:5/29/2017)... May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... which enables the functional selection of stem cells, today ... the first quarter ended March 31 st , 2017. ... accomplishments in the first quarter of 2017," said Dr. ... we announced the treatment of the first blood cancer ...
(Date:5/22/2017)... 22, 2017  Lilac Corp, the company that ... launch of a new website . The ... a clinical study that showed surprising clearance of ... in individuals suffering from HPV warts, precancerous, or ... are no other treatments that clear the virus. ...
Breaking Medicine Technology: